Lewy Body Dementia clinical trials at University of California Health

4 in progress, 0 open to eligible people

Showing trials for

  • Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

    Sorry, not currently recruiting here

    The main purpose of this study is to evaluate whether treatment with donanemab slows the progression of cognitive (how we think, learn, remember, pay attention, and make decisions) and functional (how we are able to perform daily activities) decline. For each participant, the study will last one and a half years.

    at UCSD

  • Diagnostic Test for Dementia With Lewy Bodies

    Sorry, in progress, not accepting new patients

    The Syn-D Study will be evaluating α-synuclein in patients with suspected MCI-AD and MCI-DLB. Using a simple diagnostic test will improve clinical accuracy in diagnosing, earlier diagnosis, and distinguish between neurodegenerative diseases.

    at UCSD

  • North American Prodromal Synucleinopathy Consortium

    Sorry, accepting new patients by invitation only

    This study will enroll participants with idiopathic rapid eye movement (REM) sleep behavior disorder (RBD), for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.

    at UCLA

  • North American Prodromal Synucleinopathy Consortium Stage 2

    Sorry, accepting new patients by invitation only

    This study will enroll participants with idiopathic REM sleep behavior disorder (RBD) and healthy controls for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.

    at UCLA

Our lead scientists for Lewy Body Dementia research studies include .

Last updated: